GEORGE WILDING

TitleProfessor
InstitutionMD Anderson
DepartmentGenitourinary Medical Oncology
Address1515 Holcombe Blvd.
Houston TX 77030
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Basu HS, Wilganowski N, Robertson S, Reuben JM, Cohen EN, Zurita A, Ramachandran S, Xiao LC, Titus M, Wilding G. Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities. Prostate. 2021 Sep; 81(12):799-811. PMID: 34170017.
      Citations:    Fields:    
    2. Wong YN, Manola J, Hudes GR, Roth BJ, Moul JW, Barsevick AM, Scher RM, Volk MJ, Vaughn DJ, Williams SD, Fisch MJ, Cella D, Carducci MA, Wilding G. Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. Clin Genitourin Cancer. 2018 04; 16(2):e315-e322. PMID: 29173976.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    3. Engle JA, Traynor AM, Campbell TC, Wisinski KB, LoConte N, Liu G, Wilding G, Kolesar JM. Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center. J Oncol Pharm Pract. 2018 Jul; 24(5):348-353. PMID: 28457192.
      Citations:    Fields:    Translation:Humans
    4. Tang C, Sherman SI, Price M, Weng J, Davis SE, Hong DS, Yao JC, Buzdar A, Wilding G, Lee JJ. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. Clin Cancer Res. 2017 Mar 15; 23(6):1414-1421. PMID: 28275168.
      Citations: 10     Fields:    Translation:Humans
    5. Chen Y, Rini BI, Motzer RJ, Dutcher JP, Rixe O, Wilding G, Stadler WM, Tarazi J, Garrett M, Pithavala YK. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. Target Oncol. 2016 Apr; 11(2):229-34. PMID: 26400730.
      Citations: 6     Fields:    Translation:Humans
    6. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 May 14; 387(10032):2008-16. PMID: 26969090.
      Citations: 149     Fields:    Translation:HumansCTClinical Trials
    7. Kyriakopoulos CE, Heath EI, Eickhoff JC, Kolesar J, Yayehyirad M, Moll T, Wilding G, Liu G. A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer. Invest New Drugs. 2016 Apr; 34(2):225-30. PMID: 26924129.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    8. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20; 34(12):1402-18. PMID: 26903579.
      Citations: 249     Fields:    Translation:Humans
    9. Deming DA, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Eickhoff JC, Kolesar JM, Fioravanti S, Greten TF, Compton K, Doyle AG, Wilding G, Duffy A, Liu G. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Invest New Drugs. 2016 Apr; 34(2):168-75. PMID: 26666244.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    10. Mehraein-Ghomi F, Church DR, Schreiber CL, Weichmann AM, Basu HS, Wilding G. Inhibitor of p52 NF-?B subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated AR(ser81). Genes Cancer. 2015 Sep; 6(9-10):428-44. PMID: 26622945.
      Citations: 2     
    11. Carducci MA, Manola J, Nair SG, Liu G, Rousey S, Dutcher JP, Wilding G. Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800). Clin Genitourin Cancer. 2015 Dec; 13(6):531-539.e1. PMID: 26272427.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    12. Huang SX, Yun BS, Ma M, Basu HS, Church DR, Ingenhorst G, Huang Y, Yang D, Lohman JR, Tang GL, Ju J, Liu T, Wilding G, Shen B. Leinamycin E1 acting as an anticancer prodrug activated by reactive oxygen species. Proc Natl Acad Sci U S A. 2015 Jul 07; 112(27):8278-83. PMID: 26056295.
      Citations: 11     Fields:    Translation:HumansCells
    13. Wisinski KB, Cantu CA, Eickhoff J, Osterby K, Tevaarwerk AJ, Heideman J, Liu G, Wilding G, Johnston S, Kolesar JM. Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. Am J Health Syst Pharm. 2015 Jun 01; 72(11):958-65. PMID: 25987691.
      Citations: 2     Fields:    Translation:Humans
    14. Haas NB, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane CJ, Jewett M, Wood L, Wood CG, Atkins MB, Dutcher JJ, Wilding G, DiPaola RS. Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. Clin Cancer Res. 2015 Sep 15; 21(18):4048-54. PMID: 25967143.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    15. Huang W, Eickhoff JC, Mehraein-Ghomi F, Church DR, Wilding G, Basu HS. Expression of spermidine/spermine N(1) -acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis. Prostate. 2015 Aug 01; 75(11):1150-9. PMID: 25893668.
      Citations: 16     Fields:    Translation:Humans
    16. DiPaola RS, Chen YH, Bubley GJ, Stein MN, Hahn NM, Carducci MA, Lattime EC, Gulley JL, Arlen PM, Butterfield LH, Wilding G. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. Eur Urol. 2015 Sep; 68(3):365-71. PMID: 25533418.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    17. Wisinski KB, Ledesma WM, Kolesar J, Wilding G, Liu G, Douglas J, Traynor AM, Albertini M, Mulkerin D, Bailey HH. A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1a,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract. 2015 Dec; 21(6):416-24. PMID: 24986793.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    18. McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, Staab MJ, Liu G, Wilding G, Olson BM. Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. Clin Cancer Res. 2014 Jul 15; 20(14):3692-704. PMID: 24850844.
      Citations: 24     Fields:    Translation:HumansPHPublic Health
    19. Mehraein-Ghomi F, Kegel SJ, Church DR, Schmidt JS, Reuter QR, Saphner EL, Basu HS, Wilding G. Targeting androgen receptor and JunD interaction for prevention of prostate cancer progression. Prostate. 2014 May; 74(7):792-803. PMID: 24647988.
      Citations: 4     Fields:    Translation:HumansCells
    20. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013 Dec; 14(13):1307-16. PMID: 24211163.
      Citations: 84     Fields:    Translation:HumansCTClinical Trials
    21. Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, Schelman WR. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Invest New Drugs. 2014 Apr; 32(2):323-9. PMID: 24114123.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    22. Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 2013 Dec; 31(6):1539-46. PMID: 24114121.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    23. Kolesar JM, Traynor AM, Holen KD, Hoang T, Seo S, Kim K, Alberti D, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH, Schelman WR. Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes. Cancer Chemother Pharmacol. 2013 Sep; 72(3):661-7. PMID: 23903894.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    24. Schelman WR, Mohammed TA, Traynor AM, Kolesar JM, Marnocha RM, Eickhoff J, Keppen M, Alberti DB, Wilding G, Takebe N, Liu G. A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Invest New Drugs. 2014 Apr; 32(2):295-302. PMID: 23860642.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    25. Lang JM, Wallace M, Becker JT, Eickhoff JC, Buehring B, Binkley N, Staab MJ, Wilding G, Liu G, Malkovsky M, McNeel DG. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clin Genitourin Cancer. 2013 Dec; 11(4):407-15. PMID: 23835291.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    26. Rathkopf DE, Picus J, Hussain A, Ellard S, Chi KN, Nydam T, Allen-Freda E, Mishra KK, Porro MG, Scher HI, Wilding G. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2013 Sep; 72(3):537-44. PMID: 23820963.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    27. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013 Aug; 14(9):882-92. PMID: 23810788.
      Citations: 198     Fields:    Translation:HumansCTClinical Trials
    28. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 04; 368(14):1314-25. PMID: 23550669.
      Citations: 133     Fields:    Translation:Humans
    29. Rini BI, Garrett M, Poland B, Dutcher JP, Rixe O, Wilding G, Stadler WM, Pithavala YK, Kim S, Tarazi J, Motzer RJ. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol. 2013 May; 53(5):491-504. PMID: 23553560.
      Citations: 40     Fields:    Translation:Humans
    30. Gee J, Bailey H, Kim K, Kolesar J, Havighurst T, Tutsch KD, See W, Cohen MB, Street N, Levan L, Jarrard D, Wilding G. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1a-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate. 2013 Jun; 73(9):970-8. PMID: 23335089.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    31. Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford ED, Vogelzang NJ, Powell IJ, Thompson IM. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol. 2012 Oct; 188(4):1164-9. PMID: 22921015.
      Citations: 30     Fields:    Translation:Humans
    32. Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, Isaacs JT. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med. 2012 Jun 27; 4(140):140ra86. PMID: 22745436.
      Citations: 74     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    33. Amato RJ, Wilding G, Bubley G, Loewy J, Haluska F, Gross ME. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clin Genitourin Cancer. 2012 Dec; 10(4):232-8. PMID: 22695254.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    34. Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012 Apr 20; 30(12):1371-7. PMID: 22430274.
      Citations: 80     Fields:    Translation:HumansCTClinical Trials
    35. Liu G, Chen YH, Dipaola R, Carducci M, Wilding G. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. Clin Genitourin Cancer. 2012 Jun; 10(2):99-105. PMID: 22386239.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    36. McNeel DG, Smith HA, Eickhoff JC, Lang JM, Staab MJ, Wilding G, Liu G. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother. 2012 Jul; 61(7):1137-47. PMID: 22210552.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    37. Liu G, Jeraj R, Vanderhoek M, Perlman S, Kolesar J, Harrison M, Simoncic U, Eickhoff J, Carmichael L, Chao B, Marnocha R, Ivy P, Wilding G. Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clin Cancer Res. 2011 Dec 15; 17(24):7634-44. PMID: 22038997.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    38. Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, Kozloff M, Mathew P, Harmon CS, Wang SL, Chen I, Chow Maneval E, Logothetis CJ. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Ann Oncol. 2012 Mar; 23(3):688-694. PMID: 21821830.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    39. Lin J, Zahurak M, Beer TM, Ryan CJ, Wilding G, Mathew P, Morris M, Callahan JA, Gordon G, Reich SD, Carducci MA, Antonarakis ES. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. Urol Oncol. 2013 Jul; 31(5):581-8. PMID: 21816640.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    40. Liu G, Chen YH, Kolesar J, Huang W, Dipaola R, Pins M, Carducci M, Stein M, Bubley GJ, Wilding G. Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urol Oncol. 2013 Feb; 31(2):211-8. PMID: 21784672.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    41. Lang JM, Kaikobad MR, Wallace M, Staab MJ, Horvath DL, Wilding G, Liu G, Eickhoff JC, McNeel DG, Malkovsky M. Pilot trial of interleukin-2 and zoledronic acid to augment ?d T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother. 2011 Oct; 60(10):1447-60. PMID: 21647691.
      Citations: 58     Fields:    Translation:HumansCellsCTClinical Trials
    42. Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC, Paliwal P, Fizazi K. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology. 2011 May; 77(5):1166-71. PMID: 21539969.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    43. Cetnar J, Wilding G, McNeel D, LoConte NK, McFarland TA, Eickhoff J, Liu G. A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urol Oncol. 2013 May; 31(4):436-41. PMID: 21481618.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    44. Ryan RM, Wilding GE, Wynn RJ, Welliver RC, Holm BA, Leach CL. Effect of enhanced ultraviolet germicidal irradiation in the heating ventilation and air conditioning system on ventilator-associated pneumonia in a neonatal intensive care unit. J Perinatol. 2011 Sep; 31(9):607-14. PMID: 21436785.
      Citations: 1     Fields:    Translation:Humans
    45. Holen K, DiPaola R, Liu G, Tan AR, Wilding G, Hsu K, Agrawal N, Chen C, Xue L, Rosenberg E, Stein M. A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors. Invest New Drugs. 2012 Jun; 30(3):1088-95. PMID: 21424701.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    46. Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012 Jun; 29(2):761-7. PMID: 21298497.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    47. Tevaarwerk A, Wilding G, Eickhoff J, Chappell R, Sidor C, Arnott J, Bailey H, Schelman W, Liu G. Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Invest New Drugs. 2012 Jun; 30(3):1039-45. PMID: 21225315.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    48. Kolesar JM, Sachidanandam K, Schelman WR, Eickhoff J, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE. Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance. Exp Ther Med. 2011 Jan; 2(1):119-123. PMID: 21373381.
      Citations: 2     
    49. Bruce JY, Eickhoff J, Pili R, Logan T, Carducci M, Arnott J, Treston A, Wilding G, Liu G. A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Invest New Drugs. 2012 Apr; 30(2):794-802. PMID: 21174224.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    50. Heath EI, Blumenschein GR, Cohen RB, Lorusso PM, Loconte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemother Pharmacol. 2011 Sep; 68(3):703-12. PMID: 21140147.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    51. Rathkopf D, Liu G, Carducci MA, Eisenberger MA, Anand A, Morris MJ, Slovin SF, Sasaki Y, Takahashi S, Ozono S, Fung NK, Cheng S, Gan J, Gottardis M, Obermeier MT, Reddy J, Zhang S, Vakkalagadda BJ, Alland L, Wilding G, Scher HI. Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clin Cancer Res. 2011 Feb 15; 17(4):880-7. PMID: 21131556.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    52. Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst. 2010 Oct 20; 102(20):1536-46. PMID: 20858887.
      Citations: 249     Fields:    Translation:HumansAnimals
    53. Basu HS, Mahlum A, Mehraein-Ghomi F, Kegel SJ, Guo S, Peters NR, Wilding G. Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA). Cancer Chemother Pharmacol. 2011 Mar; 67(3):705-15. PMID: 20512578.
      Citations: 7     Fields:    Translation:HumansCells
    54. Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest New Drugs. 2011 Dec; 29(6):1465-74. PMID: 20499131.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    55. Holen KD, Belani CP, Wilding G, Ramalingam S, Volkman JL, Ramanathan RK, Vasist LS, Bowen CJ, Hodge JP, Dar MM, Ho PT. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemother Pharmacol. 2011 Feb; 67(2):447-54. PMID: 20461380.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    56. Mehraein-Ghomi F, Basu HS, Church DR, Hoffmann FM, Wilding G. Androgen receptor requires JunD as a coactivator to switch on an oxidative stress generation pathway in prostate cancer cells. Cancer Res. 2010 Jun 01; 70(11):4560-8. PMID: 20460526.
      Citations: 16     Fields:    Translation:HumansCells
    57. Kolesar J, Brundage RC, Pomplun M, Alberti D, Holen K, Traynor A, Ivy P, Wilding G. Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients. Cancer Chemother Pharmacol. 2011 Feb; 67(2):393-400. PMID: 20440618.
      Citations: 6     Fields:    Translation:HumansCells
    58. Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ, Scott BB, Leighton AM, Watson PA, Zhao B, O'Dwyer PJ, Wilding G. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011 Feb; 67(2):305-14. PMID: 20386909.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    59. DiPaola RS, Chen YH, Stein M, Vaughn D, Patrick-Miller L, Carducci M, Roth B, White E, Wilding G. A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. J Transl Med. 2010 Feb 24; 8:20. PMID: 20178647.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    60. Choi BS, Alberti DB, Schelman WR, Kolesar JM, Thomas JP, Marnocha R, Eickhoff JC, Ivy SP, Wilding G, Holen KD. The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. Cancer Chemother Pharmacol. 2010 Oct; 66(5):973-80. PMID: 20127092.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    61. Kloetzer L, Chey WD, McCallum RW, Koch KL, Wo JM, Sitrin M, Katz LA, Lackner JM, Parkman HP, Wilding GE, Semler JR, Hasler WL, Kuo B. Motility of the antroduodenum in healthy and gastroparetics characterized by wireless motility capsule. Neurogastroenterol Motil. 2010 May; 22(5):527-33, e117. PMID: 20122128.
      Citations: 28     Fields:    Translation:Humans
    62. Traynor AM, Thomas JP, Ramanathan RK, Mody TD, Alberti D, Wilding G, Bailey HH. Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies. Invest New Drugs. 2011 Apr; 29(2):316-22. PMID: 19997959.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    63. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, Calabrò F, Cheng S, Trudel GC, Paliwal P, Sternberg CN. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Dec 01; 15(23):7421-8. PMID: 19920114.
      Citations: 91     Fields:    Translation:HumansCTClinical Trials
    64. Burris HA, Taylor CW, Jones SF, Koch KM, Versola MJ, Arya N, Fleming RA, Smith DA, Pandite L, Spector N, Wilding G. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res. 2009 Nov 01; 15(21):6702-8. PMID: 19825948.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    65. Basu HS, Thompson TA, Church DR, Clower CC, Mehraein-Ghomi F, Amlong CA, Martin CT, Woster PM, Lindstrom MJ, Wilding G. A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2009 Oct 01; 69(19):7689-95. PMID: 19773450.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    66. Schelman WR, Liu G, Wilding G, Morris T, Phung D, Dreicer R. A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Invest New Drugs. 2011 Feb; 29(1):118-25. PMID: 19763400.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    67. Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ, Wilding G. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer. 2009 Sep 15; 115(18):4090-5. PMID: 19536901.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    68. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 20; 27(27):4462-8. PMID: 19652060.
      Citations: 115     Fields:    Translation:HumansCTClinical Trials
    69. LoConte NK, Smith M, Alberti D, Bozeman J, Cleary JF, Setala AN, Wodtke G, Wilding G, Holen KD. Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy. Cancer Chemother Pharmacol. 2010 Mar; 65(4):775-80. PMID: 19649630.
      Citations: 6     Fields:    Translation:Humans
    70. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol. 2009 Sep 01; 27(25):4047-54. PMID: 19636017.
      Citations: 110     Fields:    Translation:HumansCellsCTClinical Trials
    71. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Aug 01; 27(22):3584-90. PMID: 19487381.
      Citations: 702     Fields:    Translation:HumansCTClinical Trials
    72. Traynor AM, Gordon MS, Alberti D, Mendelson DS, Munsey MS, Wilding G, Gammans RE, Read WL. A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors. Invest New Drugs. 2010 Aug; 28(4):509-15. PMID: 19434370.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    73. Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, Dipaola RS, Crawford ED. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol. 2009 May 20; 27(15):2450-6. PMID: 19380444.
      Citations: 54     Fields:    Translation:HumansCTClinical Trials
    74. Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res. 2009 May 01; 15(9):3172-6. PMID: 19366825.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    75. Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS, Groteluschen DL, Marcotte SM, Hallahan CM, Weeks HR, Wilding G, Espinoza-Delgado I, Schiller JH. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol. 2009 Apr; 4(4):522-6. PMID: 19347984.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    76. Tevaarwerk AJ, Holen KD, Alberti DB, Sidor C, Arnott J, Quon C, Wilding G, Liu G. Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1460-5. PMID: 19228747.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    77. Motzer RJ, Hudes G, Wilding G, Schwartz LH, Hariharan S, Kempin S, Fayyad R, Figlin RA. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2009 Jan; 7(1):28-33. PMID: 19213665.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    78. Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer. 2009 Jan; 7(1):51-7. PMID: 19213669.
      Citations: 9     Fields:    Translation:Humans
    79. Schelman WR, Morgan-Meadows S, Marnocha R, Lee F, Eickhoff J, Huang W, Pomplun M, Jiang Z, Alberti D, Kolesar JM, Ivy P, Wilding G, Traynor AM. A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009 May; 63(6):1147-56. PMID: 19082825.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    80. Ricart AD, Tolcher AW, Liu G, Holen K, Schwartz G, Albertini M, Weiss G, Yazji S, Ng C, Wilding G. Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res. 2008 Dec 01; 14(23):7924-9. PMID: 19047123.
      Citations: 59     Fields:    Translation:HumansCellsCTClinical Trials
    81. Kolesar J, Huang W, Eickhoff J, Hahn K, Alberti D, Attia S, Schelman W, Holen K, Traynor A, Ivy P, Wilding G. Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. Cancer Chemother Pharmacol. 2009 Jun; 64(1):79-86. PMID: 18941749.
      Citations: 8     Fields:    Translation:Humans
    82. Attia S, Morgan-Meadows S, Holen KD, Bailey HH, Eickhoff JC, Schelman WR, Traynor AM, Mulkerin DL, Campbell TC, McFarland TA, Huie MS, Cleary JF, Tevaarwerk AJ, Alberti DB, Wilding G, Liu G. Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemother Pharmacol. 2009 Jun; 64(1):45-51. PMID: 18841362.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    83. Ignatoff JM, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group. Urol Oncol. 2009 Sep-Oct; 27(5):496-501. PMID: 18639470.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    84. Dreicer R, Li H, Cooney MM, Wilding G, Roth BJ. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group. Cancer. 2008 Jun 15; 112(12):2671-5. PMID: 18459175.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    85. Mehraein-Ghomi F, Lee E, Church DR, Thompson TA, Basu HS, Wilding G. JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells. Prostate. 2008 Jun 15; 68(9):924-34. PMID: 18386285.
      Citations: 21     Fields:    Translation:HumansCells
    86. Shivakumar R, Tan W, Wilding GE, Wang ES, Wetzler M. Biologic features and treatment outcome of secondary acute lymphoblastic leukemia--a review of 101 cases. Ann Oncol. 2008 Sep; 19(9):1634-8. PMID: 18467310.
      Citations: 15     Fields:    Translation:Humans
    87. Lardy H, Marwah A, Zhong W, Moore R, Marwah P, Thompson T, Wilding G. A test of rats' tolerance for 3beta-acetoxyandrosta-1,5-dien-17-one ethylene ketal (ADEK), a new anti-androgen. J Steroid Biochem Mol Biol. 2008 Jul; 111(1-2):60-5. PMID: 18539452.
      Citations:    Fields:    Translation:AnimalsCells
    88. Liu G, Kolesar J, McNeel DG, Leith C, Schell K, Eickhoff J, Lee F, Traynor A, Marnocha R, Alberti D, Zwiebel J, Wilding G. A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors. Clin Cancer Res. 2008 May 01; 14(9):2732-9. PMID: 18451239.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    89. Attia S, Eickhoff J, Wilding G, McNeel D, Blank J, Ahuja H, Jumonville A, Eastman M, Shevrin D, Glode M, Alberti D, Staab MJ, Horvath D, Straus J, Marnocha R, Liu G. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res. 2008 Apr 15; 14(8):2437-43. PMID: 18413835.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    90. Brennan-Calanan RM, Genco RJ, Wilding GE, Hovey KM, Trevisan M, Wactawski-Wende J. Osteoporosis and oral infection: independent risk factors for oral bone loss. J Dent Res. 2008 Apr; 87(4):323-7. PMID: 18362312.
      Citations: 11     Fields:    Translation:HumansCells
    91. LoConte NK, Thomas JP, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, Kolesar J. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. Cancer Chemother Pharmacol. 2008 Dec; 63(1):109-15. PMID: 18322686.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    92. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 01; 26(7):1148-59. PMID: 18309951.
      Citations: 740     Fields:    Translation:Humans
    93. Schelman W, Morgan-Meadows S, Bailey H, Holen K, Thomas JP, Eickhoff J, Brandon H, Oliver K, Alberti D, Wilding G. A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008 Sep; 62(4):727-33. PMID: 18172649.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    94. Lalich M, McNeel DG, Wilding G, Liu G. Endothelin receptor antagonists in cancer therapy. Cancer Invest. 2007 Dec; 25(8):785-94. PMID: 18058475.
      Citations: 21     Fields:    Translation:HumansCells
    95. Kolesar JM, Schelman WR, Geiger PG, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE. Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine. J Inorg Biochem. 2008 Apr; 102(4):693-8. PMID: 18061679.
      Citations: 7     Fields:    Translation:HumansCells
    96. Kuo B, McCallum RW, Koch KL, Sitrin MD, Wo JM, Chey WD, Hasler WL, Lackner JM, Katz LA, Semler JR, Wilding GE, Parkman HP. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther. 2008 Jan 15; 27(2):186-96. PMID: 17973643.
      Citations: 87     Fields:    Translation:Humans
    97. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007 Nov; 8(11):975-84. PMID: 17959415.
      Citations: 133     Fields:    Translation:HumansCTClinical Trials
    98. Hutson PR, Oettel K, Douglas J, Ritter M, Messing E, Staab MJ, Alberti D, Horvath D, Wilding G. Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test. Cancer Chemother Pharmacol. 2008 Aug; 62(3):373-7. PMID: 17922273.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    99. Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, Iacona RB, Kabbinavar FF. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int. 2007 Oct; 100(4):765-9. PMID: 17822457.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    100. Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G. Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007 Nov; 178(5):1883-7. PMID: 17868732.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    101. Aziz MH, Manoharan HT, Church DR, Dreckschmidt NE, Zhong W, Oberley TD, Wilding G, Verma AK. Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. Cancer Res. 2007 Sep 15; 67(18):8828-38. PMID: 17875724.
      Citations: 68     Fields:    Translation:HumansAnimalsCells
    102. Dreicer R, Li S, Manola J, Haas NB, Roth BJ, Wilding G. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer. 2007 Aug 15; 110(4):759-63. PMID: 17594721.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    103. Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007 Aug 01; 110(3):556-63. PMID: 17577218.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    104. Bailey HH, Alberti DB, Thomas JP, Mulkerin DL, Binger KA, Gottardis MM, Martell RE, Wilding G. Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors. Clin Cancer Res. 2007 Jun 15; 13(12):3623-9. PMID: 17510207.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    105. Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger MA. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May; 177(5):1777-81. PMID: 17437819.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    106. Zhang D, Pier T, McNeel DG, Wilding G, Friedl A. Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study. Invest New Drugs. 2007 Feb; 25(1):49-55. PMID: 17001523.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    107. Attia S, Wilding G. Novel antioxidant technology for prostate cancer chemoprevention and treatment. Expert Opin Ther Pat. 2006 Sep; 16(9):1255-67. PMID: 20144058.
      Citations:    Fields:    
    108. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006 Aug 20; 24(24):3984-90. PMID: 16921051.
      Citations: 135     Fields:    Translation:Humans
    109. Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, Saltzstein D, Wilding G. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol. 2006 Aug; 176(2):500-4. PMID: 16813878.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    110. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006 Jun 07; 295(21):2516-24. PMID: 16757724.
      Citations: 322     Fields:    Translation:HumansCTClinical Trials
    111. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006 Jun; 7(6):472-9. PMID: 16750497.
      Citations: 172     Fields:    Translation:Humans
    112. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006 Jul; 14(1):107-17. PMID: 16690359.
      Citations: 80     Fields:    Translation:HumansCellsCTClinical Trials
    113. Wilding G, Soulie P, Trump D, Das-Gupta A, Small E. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer. 2006 May 01; 106(9):1917-24. PMID: 16568471.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    114. Huie M, Oettel K, Van Ummersen L, Kim KM, Zhang Y, Staab MJ, Horvath D, Marnocha R, Douglas J, Drezen A, Alberti D, Wilding G. Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma. Invest New Drugs. 2006 May; 24(3):255-60. PMID: 16205854.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    115. Gray R, Manola J, Saxman S, Wright J, Dutcher J, Atkins M, Carducci M, See W, Sweeney C, Liu G, Stein M, Dreicer R, Wilding G, DiPaola RS. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):1966-9. PMID: 16609005.
      Citations: 8     Fields:    Translation:Humans
    116. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jan 01; 24(1):16-24. PMID: 16330672.
      Citations: 363     Fields:    Translation:HumansCTClinical Trials
    117. Zlotocha S, Staab MJ, Horvath D, Straus J, Dobratz J, Oliver K, Wasielewski S, Alberti D, Liu G, Wilding G, Eickhoff J, McNeel DG. A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancer. Clin Genitourin Cancer. 2005 Dec; 4(3):215-8. PMID: 16425992.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    118. Huie M, Carducci M, Liu G, Wilding G, Marnocha R, Izquierda M, Thomas J. Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors. Am J Clin Oncol. 2005 Dec; 28(6):613-7. PMID: 16317274.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    119. Dubey S, Hutson P, Alberti D, Arzoomanian R, Binger K, Volkman J, Feierabend C, Wilding G, Schiller JH. Phase I study of docetaxel and topotecan in patients with advanced malignancies. J Oncol Pharm Pract. 2005 Dec; 11(4):131-8. PMID: 16595064.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    120. Dutcher JP, Leon L, Manola J, Friedland DM, Roth B, Wilding G. Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study. Cancer. 2005 Dec 01; 104(11):2392-9. PMID: 16222691.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    121. McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res. 2005 Nov 01; 11(21):7851-60. PMID: 16278408.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    122. Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, Wilding G. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6625-33. PMID: 16166441.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    123. Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol. 2005 Aug 20; 23(24):5464-73. PMID: 16027440.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    124. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005 Aug 20; 23(24):5474-83. PMID: 16027439.
      Citations: 139     Fields:    Translation:HumansCTClinical Trials
    125. Church DR, Lee E, Thompson TA, Basu HS, Ripple MO, Ariazi EA, Wilding G. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells. Prostate. 2005 May 01; 63(2):155-68. PMID: 15486991.
      Citations: 12     Fields:    Translation:HumansCells
    126. Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res. 2005 May 01; 11(9):3410-6. PMID: 15867242.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    127. Hegeman RB, Liu G, Wilding G, McNeel DG. Newer therapies in advanced prostate cancer. Clin Prostate Cancer. 2004 Dec; 3(3):150-6. PMID: 15636681.
      Citations: 9     Fields:    Translation:Humans
    128. Wilding G, Remington P. Period analysis of prostate cancer survival. J Clin Oncol. 2005 Jan 20; 23(3):407-9. PMID: 15572729.
      Citations:    Fields:    Translation:Humans
    129. Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J, Arzoomanian R, Alberti D, Wilding G. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res. 2004 Nov 15; 10(22):7450-6. PMID: 15569974.
      Citations: 47     Fields:    Translation:HumansCellsCTClinical Trials
    130. Ahles TA, Herndon JE, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15; 101(10):2202-8. PMID: 15484217.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    131. Schulz CA, Mehta MP, Badie B, McGinn CJ, Robins HI, Hayes L, Chappell R, Volkman J, Binger K, Arzoomanian R, Simon K, Alberti D, Feierabend C, Tutsch KD, Kunugi KA, Wilding G, Kinsella TJ. Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study. Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59(4):1107-15. PMID: 15234045.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    132. Bailey HH, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Marnocha R, Holstein SA, Stewart J, Lewis KA, Hohl RJ. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. Cancer Chemother Pharmacol. 2004 Oct; 54(4):368-76. PMID: 15205914.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    133. Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, Whiteside TL, Schlom J, Wilding G, Weiner LM. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2004 Jun 01; 22(11):2122-32. PMID: 15169798.
      Citations: 80     Fields:    Translation:HumansCTClinical Trials
    134. Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer. 2004 Apr 15; 100(8):1639-45. PMID: 15073851.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    135. Forouzannia A, Schiller J, Berlin J, Hutson P, Boothman D, Storer B, Wilding G, Mehta M. A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies. Lung Cancer. 2004 Apr; 44(1):111-9. PMID: 15013589.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    136. Wilding G, King D, Tutsch K, Pomplun M, Feierabend C, Alberti D, Arzoomanian R. Phase I trial of the polyamine analog N1,N14-diethylhomospermine (DEHSPM) in patients with advanced solid tumors. Invest New Drugs. 2004 Apr; 22(2):131-8. PMID: 14739661.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    137. Hande KR, Collier M, Paradiso L, Stuart-Smith J, Dixon M, Clendeninn N, Yeun G, Alberti D, Binger K, Wilding G. Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Clin Cancer Res. 2004 Feb 01; 10(3):909-15. PMID: 14871966.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    138. Liu G, Gandara DR, Lara PN, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res. 2004 Feb 01; 10(3):924-8. PMID: 14871968.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    139. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 01; 22(3):537-56. PMID: 14752077.
      Citations: 57     Fields:    Translation:Humans
    140. Frydman B, Blokhin AV, Brummel S, Wilding G, Maxuitenko Y, Sarkar A, Bhattacharya S, Church D, Reddy VK, Kink JA, Marton LJ, Valasinas A, Basu HS. Cyclopropane-containing polyamine analogues are efficient growth inhibitors of a human prostate tumor xenograft in nude mice. J Med Chem. 2003 Oct 09; 46(21):4586-600. PMID: 14521420.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    141. Liu G, Wilding G, Staab MJ, Horvath D, Miller K, Dresen A, Alberti D, Arzoomanian R, Chappell R, Bailey HH. Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. Clin Cancer Res. 2003 Sep 15; 9(11):4077-83. PMID: 14519629.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    142. Morgan-Meadows S, Dubey S, Gould M, Tutsch K, Marnocha R, Arzoomanin R, Alberti D, Binger K, Feierabend C, Volkman J, Ellingen S, Black S, Pomplun M, Wilding G, Bailey H. Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemother Pharmacol. 2003 Nov; 52(5):361-6. PMID: 12904896.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    143. Thompson TA, Wilding G. Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells. Mol Cancer Ther. 2003 Aug; 2(8):797-803. PMID: 12939470.
      Citations: 13     Translation:HumansCells
    144. Liu G, Oettel K, Bailey H, Ummersen LV, Tutsch K, Staab MJ, Horvath D, Alberti D, Arzoomanian R, Rezazadeh H, McGovern J, Robinson E, DeMets D, Wilding G. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Invest New Drugs. 2003 Aug; 21(3):367-72. PMID: 14578686.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    145. Stadler W, Wilding G. Angiogenesis inhibitors in genitourinary cancers. Crit Rev Oncol Hematol. 2003 Jun 27; 46 Suppl:S41-7. PMID: 12850526.
      Citations: 2     Fields:    Translation:Humans
    146. Dreicer R, Manola J, Schneider DJ, Schwerkoske JF, George CS, Roth BJ, Wilding G. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer. 2003 Jun 01; 97(11):2743-7. PMID: 12767086.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    147. Liu G, Bailey HH, Arzoomanian RZ, Alberti D, Binger K, Volkman J, Feierabend C, Marnocha R, Wilding G, Thomas JP. Gemcitabine, Paclitaxel, and piritrexim: a phase I study. Am J Clin Oncol. 2003 Jun; 26(3):280-4. PMID: 12796601.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    148. Bauer JA, Thompson TA, Church DR, Ariazi EA, Wilding G. Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha,24-dihydroxyvitamin D2. Prostate. 2003 May 15; 55(3):159-67. PMID: 12692781.
      Citations: 10     Fields:    Translation:HumansCells
    149. Dreicer R, Roth B, Wilding G. Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group. Cancer. 2003 Apr 15; 97(8 Suppl):2109-14. PMID: 12673703.
      Citations:    Fields:    Translation:Humans
    150. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol. 2003 Apr 01; 21(7):1214-22. PMID: 12663707.
      Citations: 60     Fields:    Translation:HumansCTClinical Trials
    151. Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J, Fogler W, Schiller JH, Wilding G. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2003 Jan 15; 21(2):223-31. PMID: 12525513.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    152. Skeel RT, Huang J, Manola J, Wilding G, Dreicer R, Walker P, Muggia F, Crawford ED, Dutcher JP, Loehrer PJ. A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893). Cancer Invest. 2003; 21(1):41-6. PMID: 12643008.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    153. Lee YF, Lin WJ, Huang J, Messing EM, Chan FL, Wilding G, Chang C. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Res. 2002 Nov 01; 62(21):6039-44. PMID: 12414626.
      Citations: 10     Fields:    Translation:HumansCells
    154. Morgan-Meadows S, Thomas JP, Mulkerin D, Berlin JD, Bailey H, Binger K, Volkman J, Alberti D, Feierabend C, Marrocha R, Arzoomanian RZ, Wilding G. Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy. Invest New Drugs. 2002 Nov; 20(4):377-82. PMID: 12448654.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    155. Roth BJ, Manola J, Dreicer R, Graham D, Wilding G. Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group. Invest New Drugs. 2002 Nov; 20(4):425-9. PMID: 12448661.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    156. Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, Simon K, Feierabend C, Binger K, Marnocha R, Dresen A, Wilding G. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol. 2002 Dec; 50(6):465-72. PMID: 12451473.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    157. Vaughn DJ, Manola J, Dreicer R, See W, Levitt R, Wilding G. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer. 2002 Sep 01; 95(5):1022-7. PMID: 12209686.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    158. Liu G, Oettel K, Ripple G, Staab MJ, Horvath D, Alberti D, Arzoomanian R, Marnocha R, Bruskewitz R, Mazess R, Bishop C, Bhattacharya A, Bailey H, Wilding G. Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. Clin Cancer Res. 2002 Sep; 8(9):2820-7. PMID: 12231522.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    159. Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 2002 Aug 15; 20(16):3369-75. PMID: 12177096.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    160. Merchant J, Tutsch K, Dresen A, Arzoomanian R, Alberti D, Feierabend C, Binger K, Marnoccha R, Thomas J, Cleary J, Wilding G. Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats. Clin Cancer Res. 2002 Jul; 8(7):2193-201. PMID: 12114420.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    161. Hinton S, Catalano P, Einhorn LH, Loehrer PJ, Kuzel T, Vaughn D, Wilding G. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2002 Apr 01; 20(7):1859-63. PMID: 11919245.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    162. Liu G, Berlin J, Tutsch KD, Van Ummersen L, Dresen A, Marnocha R, Arzomanian R, Alberti D, Feierabend C, Binger K, Wilding G. Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy. Clin Cancer Res. 2002 Mar; 8(3):706-11. PMID: 11895899.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    163. Berlin J, Tutsch KD, Arzoomanian RZ, Alberti D, Binger K, Feierabend C, Dresen A, Marnocha R, Pluda J, Wilding G. Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food. Clin Cancer Res. 2002 Jan; 8(1):86-94. PMID: 11801543.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    164. Lieberman R, Nelson WG, Sakr WA, Meyskens FL, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations. Urology. 2001 Apr; 57(4 Suppl 1):4-27. PMID: 11295590.
      Citations: 2     Fields:    Translation:Humans
    165. A phase i study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. Journal of Oncology Pharmacy Practice. 21:416-424.
    166. In reply. Journal of Clinical Oncology. 26:3648-3649.
    167. Effects of adjuvant sorafenib and sunitinib on cardiac function in renal cell carcinoma patients without overt metastases. Clinical Cancer Research. 21:4048-4054.
    168. Cytotoxic evaluation of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in peripheral blood lymphocytes of patients with refractory solid tumors using electron paramagnetic resonance. Experimental and Therapeutic Medicine. 2:119-123.
    169. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy (Science Translational Medicine). Science Translational Medicine. 4.
    170. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805). The Lancet.
    171. Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. American Journal of Health-System Pharmacy. 72:958-965.
    172. A phase i study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Investigational New Drugs. 34:168-175.
    173. Inhibitor of p52 NF-κB subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated ARser81 . Genes and Cancer. 6:428-444.
    174. A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin e 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer. Investigational New Drugs. 34:225-230.
    175. Trial design and objectives for castration-resistant prostate cancer. Journal of Clinical Oncology. 34:1402-1418.
    176. Analyses d'essais cliniques. Cancer/Radiotherapie. 4:235-236.
    177. Mipsagargin, a novel thapsigargin-based PSMA-Activated prodrug. British Journal of Cancer. 114:986-994.
    178. Atrasentan in patients with advanced renal cell carcinoma. Clinical Genitourinary Cancer. 13:531-539e1.
    179. Hereditary and sporadic cancers respond to niraparib. Cancer Discovery. 3.
    180. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. Targeted Oncology.
    181. A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression. European Urology. 68:365-371.
    WILDING's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (596)
    Explore
    _
    Co-Authors (19)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _